Compare KWR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | VERA |
|---|---|---|
| Founded | 1918 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 1994 | 2021 |
| Metric | KWR | VERA |
|---|---|---|
| Price | $149.00 | $41.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $167.00 | $81.30 |
| AVG Volume (30 Days) | 161.1K | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $1,888,634,000.00 | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.63 | $472.48 |
| P/E Ratio | $130.35 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $111.42 | $19.07 |
| 52 Week High | $183.01 | $56.05 |
| Indicator | KWR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 58.55 |
| Support Level | $147.60 | $40.87 |
| Resistance Level | $162.79 | $43.30 |
| Average True Range (ATR) | 5.85 | 2.72 |
| MACD | -1.26 | 0.17 |
| Stochastic Oscillator | 24.54 | 59.75 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.